Xeris Pharmaceuticals Inc. (XERS) Misses Q2 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Xeris Pharmaceuticals Reports Second Quarter 2021 Financial Results and Recent Highlights
August 5, 2021 7:00 AM EDTGvoke® prescription volume up 32% versus prior quarter
Gvoke unit sales to wholesalers and other direct customers up 36% versus prior quarter
Gvoke quarterly net sales up 10% to $8.8 million versus prior quarter
Strong cash position of $116 million
FDA approved Gvoke 1mg shelf-life extension to 30 months
EIH program to move forward in early 2022 with a Phase 2 study in broader patient populations
Proposed acquisition of Strongbridge Biopharma plc on track to close early... More
